Simponi orchestrates only partial "yes" from Scots despite patient access scheme
This article was originally published in Scrip
The Scottish Medicines Consortium has accepted Merck & Co's anti-TNF-alpha monoclonal antibody Simponi (golimumab) for treating ankylosing spondylitis on the Scottish NHS, but only in doses of 50mg.The consortium has also rejected the use of Bristol-Myers Squibb's Orencia (abatacept) as a second-line treatment rheumatoid arthritis.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.